Section 232 Pharmaceutical Tariffs: What Life Sciences Importers Must Do Before July 31, 2026
The April 2, 2026 presidential proclamation imposing Section 232 tariffs on patented pharmaceutical imports did not give the life sciences industry much time to prepare. For covered importers, branded drug manufacturers, biologics CDMOs, specialty pharma companies, and clinical-stage developers importing patented drug substances and APIs from international contract manufacturing partners, the clock is running. Seventeen […]